# Bioequivalence of Two Different Polymorphs of Dabigatran Etexilate in Healthy Male and Female Volunteers

> **NCT02171481** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 66 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Dabigatran etexilate polymorph II
- **DRUG:** Dabigatran etexilate polymorph I

## Key facts

- **NCT ID:** NCT02171481
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-05
- **Primary completion:** 2008-08
- **Final completion:** —
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2014-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02171481

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02171481, "Bioequivalence of Two Different Polymorphs of Dabigatran Etexilate in Healthy Male and Female Volunteers". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT02171481. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*